Publications by authors named "James A Karlowsky"

Claim this Profile
T
Trends in In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024.
Mark G Wise, James A Karlowsky, Thales J Polis, Fakhar Siddiqui, Katherine Young

Antibiotics (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro activity of ceftobiprole against 20,255 recent clinical bacterial isolates in Canada (CANWARD 2015-2023).
Élodie Gemme, Andrew Walkty, Melanie Baxter, Heather J Adam, Philippe Lagacé-Wiens, James A Karlowsky

Diagn Microbiol Infect Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23.
Philippe Lagacé-Wiens, Laura Mataseje, Melissa McCracken, Andrew Walkty, James A Karlowsky

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
George G Zhanel, Melanie R Baxter, Alyssa R Golden, Philippe Lagacé-Wiens, Andrew Walkty, James A Karlowsky

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
George G Zhanel, Melanie R Baxter, Philippe Lagacé-Wiens, Andrew Walkty, Jeff Fuller, James A Karlowsky

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007-23).
Andrew Walkty, Heather J Adam, Melanie Baxter, James A Karlowsky, Yazdan Mirzanejad

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).
Anissa Brahami, James A Karlowsky, Melissa McCracken, George R Golding, Kimberly A Nichol

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007-23).
Heather J Adam, Alyssa R Golden, Irene Martin, Melanie R Baxter, Ross J Davidson, James A Karlowsky

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007-23).
Laura F Mataseje, Nicole Lerminiaux, Philippe Lagacé-Wiens, Andrew Walkty, Heather J Adam, James A Karlowsky

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018-23).
Melissa McCracken, Andrew Walkty, Heather J Adam, Melanie Baxter, Joseph Blondeau, James A Karlowsky

J Antimicrob Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
activity of gepotidacin against urinary tract infection isolates of Enterobacterales, , and .
Meredith A Hackel, James A Karlowsky, Daniel F Sahm, Joshua M West, Nicole E Scangarella-Oman

Antimicrob Agents Chemother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-21.
John J Schellenberg, Heather J Adam, Melanie R Baxter, James A Karlowsky, Alyssa R Golden

J Antimicrob Chemother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.
James A Karlowsky, Mark G Wise, Meredith A Hackel, David A Six, Tsuyoshi Uehara

J Antimicrob Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.
George G Zhanel, Rita Dhami, Melanie Baxter, Maggie Wong, Yazdan Mirzanejad, James A Karlowsky

Expert Rev Anti Infect Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007-21.
John J Schellenberg, Heather J Adam, Melanie R Baxter, James A Karlowsky, Alyssa R Golden

J Antimicrob Chemother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
George G Zhanel, Celine Mansour, Stacey Mikolayanko, Courtney K Lawrence, Sheryl Zelenitsky, James A Karlowsky

Drugs· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How is ceftobiprole used in Canada: the CLEAR study final results.
George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, James A Karlowsky

Expert Rev Anti Infect Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
James A Karlowsky, Sibylle H Lob, Stephen P Hawser, Nimmi Kothari, Fakhar Siddiqui

Eur J Clin Microbiol Infect Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.
Mark G Wise, James A Karlowsky, Naglaa Mohamed, Elizabeth D Hermsen, Shweta Kamat

J Glob Antimicrob Resist· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, Thales Polis, Jose L Vallejo

JAC Antimicrob Resist· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
Mark G Wise, James A Karlowsky, Wei-Ting Chen, Fakhar Siddiqui, Katherine Young

J Formos Med Assoc· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21.
James A Karlowsky, Mark G Wise, Wei-Ting Chen, Fakhar Siddiqui, Katherine Young

JAC Antimicrob Resist· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
James A Karlowsky, Sibylle H Lob, Karri A Bauer, John Esterly, Fakhar Siddiqui

JAC Antimicrob Resist· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021.
Mark G Wise, James A Karlowsky, Meredith A Hackel, Mohamed Amine Harti, Bontle M E Ntshole

J Glob Antimicrob Resist· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis.
George G Zhanel, Rotem Keynan, Yoav Keynan, James A Karlowsky

Expert Rev Neurother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis